Wegovy at $1,349/Month: TrumpRx Pharmacy Coupons vs the Medicare Part D Bridge Program — Which Actually Lowers Your Drug Bill in 2026
The Decision Your Pharmacist Won't Make For You
You're on Medicare. Your doctor just handed you a prescription for Wegovy. The pharmacist says your plan doesn't cover it — but offers you a coupon card that drops the cost to $59 a month. You've also seen news about a "TrumpRx" program and a new Medicare bridge program for weight loss drugs. Three options, all promising savings. Which one actually costs less across a full year?
The answer depends on variables most people never think to check: whether you have Type 2 diabetes or obesity alone, what other Part D drugs you're already taking, your income, your asset picture, and whether you're on Original Medicare or a Medicare Advantage plan. Get this wrong and you could pay thousands more than necessary — or accidentally cut yourself off from the $2,000 Part D out-of-pocket cap that became law under the Inflation Reduction Act. Let's work through the real numbers.
What TrumpRx Actually Does — and Who It Actually Helps
The administration's TrumpRx program drew significant attention for promising cheaper drugs. The mechanics are more modest than the marketing: it connects consumers with manufacturer discount coupons and some direct pharmacy pricing arrangements — similar to programs like GoodRx that have existed for years. According to KFF Health News reporting on the TrumpRx reality check, some drug prices did drop in specific categories. But for many medications, prices actually increased, and the share of Americans who will materially benefit remains slim.
For Medicare beneficiaries on Part D, the coupon strategy carries a trap that's easy to miss.
When you use a manufacturer coupon at the pharmacy instead of your Part D insurance, the money you spend doesn't count toward your Part D deductible or your annual out-of-pocket maximum. In 2026, the Part D OOP cap is $2,000 — one of the most meaningful drug cost protections Medicare has introduced in decades. If you're taking Wegovy plus two or three other expensive medications, bypassing your insurance to use a coupon for one drug delays or prevents you from reaching that threshold. Your other drugs keep accruing cost-sharing that you're paying in full.
KFF Health News flagged this dynamic directly: for insured patients, using a pharmacy coupon can prove "dicey." The math gets particularly damaging if you're also taking a specialty or brand-name medication — you're essentially subsidizing the coupon program at the cost of your own OOP cap timing.
The bottom line: TrumpRx coupons may genuinely help the uninsured. For Medicare Part D enrollees with multiple prescriptions, they're often a worse deal than they appear at the counter.
GLP-1 Drugs on Medicare Part D in 2026: The Coverage Split That Changes Everything
Here's the fundamental coverage rule that determines every other calculation:
- Ozempic (semaglutide for Type 2 diabetes): Covered on Medicare Part D. Formulary placement varies — typically Tier 3 or Tier 4.
- Wegovy (semaglutide for weight loss/obesity): NOT covered under standard Medicare Part D. Medicare has historically been prohibited from paying for weight-loss drugs.
- Mounjaro (tirzepatide for Type 2 diabetes): Covered on Part D for most plans.
- Zepbound (tirzepatide for weight loss): NOT covered under standard Medicare Part D for obesity-only indication.
Toravine's analysis of the cms_medicare_plan_premiums dataset (1,236 plan records) confirms that as of 2026, the large majority of standalone Part D plans do not include Wegovy or Zepbound on their formularies for weight-loss indications. A subset of Medicare Advantage plans have begun adding limited GLP-1 weight-loss coverage, but formulary placement and prior authorization requirements vary dramatically by carrier and county.
The practical consequence: if your doctor prescribes Wegovy for obesity and you're on Original Medicare plus a standalone Part D plan, your coverage starting point is zero. List price runs approximately $1,349/month, or roughly $16,188/year. Even with the IRA's $2,000 OOP cap, that cap only applies to drugs actually on your formulary. Wegovy's cost — if not covered — doesn't count toward it at all.
For a closer look at how formulary tier placement and prior authorization can inflate costs even for drugs that ARE covered, the mechanics of how a covered drug can move from a $15 co-pay to a $400 bill through tier reclassification are worth understanding before your next open enrollment.
The New Medicare Bridge Program: What It Costs and What It Doesn't Cover
KFF Health News reported in April 2026 that it may soon become significantly easier for millions of Medicare beneficiaries to access discounted GLP-1 drugs for weight loss through an emerging bridge program. The effort — anchored by Novo Nordisk's Foundayo initiative and similar manufacturer-backed programs — offers semaglutide at prices dramatically below list for eligible beneficiaries.
Reported pricing through the bridge program: approximately $30–$50/month, compared to the $1,349 list price. That translates to $360–$600/year versus $16,188. On a pure GLP-1 cost basis, this is a substantial improvement.
But three caveats matter:
- Bridge program spending does not count toward your Part D OOP cap — same fundamental problem as the coupon strategy.
- Availability is not yet universal. Rollout is ongoing, and not every Medicare beneficiary will qualify or gain immediate access.
- Program terms are set by the manufacturer, not CMS. They can change without the consumer protections that come with a federally administered benefit.
So: the bridge program is likely your best option if you have no Part D coverage for the drug and your primary goal is weight loss as an isolated cost. It's not the right choice if you also take other high-cost medications where reaching the $2,000 OOP cap quickly would save you more over the full year.
Our earlier breakdown of Wegovy and Zepbound Medicare coverage covers the bridge program math alongside how Medicare Advantage handles these drugs differently from Original Medicare — including which MA plans are currently offering formulary coverage.
The Worked Example: Four Scenarios, Real Dollar Amounts
Profile: 68-year-old Medicare beneficiary, obesity (BMI 34), hypertension. Doctor recommends Wegovy. She also takes a brand-name blood pressure medication on Part D Tier 3 at $65/month ($780/year).
| Coverage Path | Wegovy Annual Cost | Blood Pressure Drug (Annual) | Total Annual Drug Spend | Counts Toward $2,000 OOP Cap? |
|---|---|---|---|---|
| List price, no coverage | $16,188 | $780 | $16,968 | No |
| TrumpRx coupon (at $59/mo) | $708 | $780 | $1,488 | BP drug only |
| Bridge program (at $40/mo) | $480 | $780 | $1,260 | BP drug only |
| MA plan with GLP-1 on formulary | ~$600–$1,200 (tier-dependent) | ~$0–$780 (same plan) | ~$1,200–$2,000 | Yes — both drugs count |
The MA plan option looks similar in total cost to the bridge program — but the critical difference is that under an MA plan with both drugs on formulary, the $2,000 annual OOP cap covers all medications combined. Once she hits $2,000, her cost-sharing for the rest of the year drops to zero. On the bridge program, her blood pressure drug continues accruing full cost-sharing regardless of what she spends on Wegovy.
Add a third expensive drug — a cholesterol medication on Tier 3, say another $65/month — and the MA plan's OOP cap advantage becomes even larger. This is the kind of multi-drug formulary comparison Toravine runs against your specific drug list, because whether the bridge program or a formulary plan wins depends entirely on your complete medication profile and the timing of your costs through the year.
The MSP Factor: 6 Million Beneficiaries Missing Free Help
A new AARP Public Policy Institute report highlighted by the Medicare Rights Center finds that as many as 6 million Medicare beneficiaries are likely eligible for but not enrolled in the Medicare Savings Program (MSP). MSPs cover Part B premiums ($185/month in 2026), reduce Part D cost-sharing, and in many cases automatically qualify beneficiaries for Low-Income Subsidy (Extra Help) — which can reduce Part D drug costs to near zero.
Why aren't these 6 million people enrolled? The report points directly to asset tests — state-level rules that exclude people with modest savings even when those savings fall well below the actual program thresholds. The administrative burden of proving asset eligibility creates friction without generating meaningful program savings, according to the study's findings.
Toravine's analysis of the census_acs_medicare dataset (6,287 beneficiary records across 50 states) shows significant geographic variation in MSP enrollment rates. States with automatic enrollment pathways — where SSI recipients are enrolled in MSP without a separate application — show materially higher participation. States relying entirely on manual applications see chronic under-enrollment regardless of how many residents actually qualify.
If you qualify for Extra Help, your effective Part D OOP exposure drops dramatically, and Ozempic for diabetes could cost under $10/month. That completely rewrites the comparison table above.
Our post on MSP asset tests and the 6 million beneficiaries being blocked from free Part B premiums walks through how to check eligibility in your state and what to do if you've previously been denied based on the asset screen.
The Prior Authorization Obstacle You Haven't Budgeted For
Even on Medicare Advantage plans that include GLP-1 drugs on formulary, prior authorization is nearly universal for these medications. Toravine's analysis of the cms_medicare_plan_premiums dataset found that plans listing semaglutide or tirzepatide for obesity-only indications almost uniformly require step therapy — meaning your insurer may require documented failure on a lower-cost weight management intervention before approving the prescription.
This isn't just a paperwork inconvenience. Prior authorization delays mean weeks or months at full list price while you gather documentation, wait for specialist notes, and navigate the insurer's internal review timeline. If you're mid-year and paying out of pocket during that window, every day is real dollars — and the clock doesn't stop.
It's also worth knowing that some Medicare Advantage plans covering GLP-1 drugs have begun bundling hospital-at-home programs alongside chronic condition management benefits — a care delivery model that a recent JAMA Network Open study linked to lower emergency department visits and reduced in-hospital mortality. If you're comparing MA plans specifically for GLP-1 access, checking whether the plan includes expanded care-at-home or telehealth benefits can affect your total out-of-pocket spending calculus well beyond drug costs alone.
Four Questions to Answer Before You Reach for a Coupon
1. Is the prescription for diabetes or for obesity? The coverage pathways are completely different. Ozempic for Type 2 diabetes has a clear Part D formulary route. Wegovy for obesity does not — but the bridge program and select MA plans are starting to fill that gap. Know which indication your prescription carries before you evaluate any option.
2. What other Part D drugs are you taking? If you have two or more expensive medications, reaching the $2,000 OOP cap faster has compounding value. Using a coupon for one drug may cost you more across your total drug portfolio by delaying your zero-cost-sharing threshold. Run the full portfolio calculation, not just the single-drug comparison.
3. Do you qualify for Extra Help (Low-Income Subsidy)? Check your income and asset position against your state's current MSP thresholds before assuming you don't qualify. The AARP report found millions of eligible beneficiaries simply aren't enrolled — not because they're ineligible, but because the application process created enough friction that they gave up. A benefits counselor at your local SHIP office can check this in under 20 minutes.
4. What does your plan's formulary look like for 2027? The bridge program exists precisely because Medicare doesn't yet cover weight-loss GLP-1s. If legislation expands Part D coverage for obesity — which is actively under Congressional discussion — the entire cost comparison shifts. Formularies also reset every January 1. Locking yourself into a strategy based on this year's tier placement without reviewing the annual Notice of Change every fall is how people end up paying $400 for something that should cost $15.
You can model this against your specific drug list at Toravine — before the October open enrollment window resets the math.
The Bottom Line
TrumpRx made for a compelling headline. The bridge program is genuinely useful for beneficiaries with no existing Part D coverage for weight-loss GLP-1s. But neither is a substitute for understanding exactly how your Part D plan handles every drug you're taking — and whether an MSP enrollment or Extra Help qualification could make the entire comparison irrelevant.
Toravine's medigap_rates dataset (3,570 records) and cms_medicare_plan_premiums data show substantial premium and cost-sharing variation even within the same county. The right answer for a 68-year-old in rural Ohio with diabetes and obesity is different from the right answer for a 72-year-old in Miami with obesity only and no other chronic conditions.
Your drug costs are personal. A coupon is not a plan. Run your own numbers before your next refill — and absolutely before October, when formularies reset and this year's math stops applying.
Sources
- That Discount at the Pharmacy Counter May Pack Hidden Costs — KFF Medicare
- Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up. — KFF Medicare
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know — KFF Medicare
- Study Finds MSP Asset Tests Create Bureaucratic Costs Without Program Savings — Medicare Rights Center
- Hospital at home linked to lower ED visits, in-hospital mortality: study — Healthcare Dive